Background: The kappa opioid receptor system has been revealed as a potential pharmacotherapeutic target for the treatment of addictions to substances of abuse. Kappa opioid receptor agonists have been shown to block the rewarding and dopamine-releasing effects of psychostimulants. Recent investigations have profiled the in vivo effects of compounds biased towards G-protein-mediated signaling, with less potent arrestin-mediated signaling. The compounds studied here derive from a series of trialkylamines: N-substituted-N-phenylethyl-N-3-hydroxyphenylethyl-amine, with N-substituents including n-butyl (BPHA), methylcyclobutyl (MCBPHA), and methylcyclopentyl (MCPPHA). Methods: BPHA, MCBPHA, and MCPPHA were characterized in vitro in a kappa opioid receptor-expressing cell line in binding assays and functional assays. We also tested the compounds in C57BL6 mice, assaying incoordination with rotarod, as well as circulating levels of the neuroendocrine kappa opioid receptor biomarker, prolactin. Results: BPHA, MCBPHA, and MCPPHA showed full kappa opioid receptor agonism for G-protein coupling compared with the reference compound U69,593. BPHA showed no measurable β-arrestin-2 recruitment, indicating that it is extremely G-protein biased. MCBPHA and MCPPHA, however, showed submaximal efficacy for recruiting β-arrestin-2. Studies in C57BL6 mice reveal that all compounds stimulate release of prolactin, consistent with dependence on G-protein signaling. MCBPHA and MCPPHA result in rotarod incoordination, whereas BPHA does not, consistent with the reported requirement of intact kappa opioid receptor/β-arrestin-2 mediated coupling for kappa opioid receptor agonist-induced rotarod incoordination. Conclusions: BPHA, MCBPHA, and MCPPHA are thus novel differentially G-protein-biased kappa opioid receptor agonists. They can be used to investigate how signaling pathways mediate kappa opioid receptor effects in vitro and in vivo and to explore the effects of candidate kappa opioid receptor-targeted pharmacotherapeutics.
Introduction
The endogenous opioid system consists of the mu, delta, and kappa opioid receptors (MOR, DOR, and KOR, respectively) as well as the closely related nociceptin receptor (NOR, also referred to as OPRL1). The opioid receptors, and the KOR in particular, play important roles in reward and addiction and therefore are promising targets for the development of therapeutics. Whereas approved medications, namely methadone (full MOR agonist) and buprenorphine/naloxone (partial MOR agonist/MOR antagonist to prevent rapid onset in the event of parenteral administration), allow for extended abstinence and recovery from opiate addiction, there are no approved medications for psychostimulant addiction. Efforts to develop new medications, or to utilize existing neurotransmitter-targeting medications, have not been successful to date. Given the immense medical, social, and economic consequences of addiction, and psychostimulant addiction in particular, continued efforts to develop medications to treat patients dependent on cocaine or other psychostimulants is essential.
Exposure to cocaine, which inhibits the biogenic amine neurotransmitter transporters, acutely causes increased extracellular dopamine, serotonin, and norepinephrine and also results in changes in components of the endogenous opioid system. Acutely, cocaine results in increased gene expression of the endogenous KOR ligand dynorphin in the dorsal and ventral striatum in animal models (Daunais et al., 1993; Spangler et al., 1993 Spangler et al., , 1996 . Chronic cocaine exposure also results in changes in MOR and KOR binding (Unterwald et al., 1992 (Unterwald et al., , 1994 Zubieta et al., 1996; Bailey et al., 2007) . Full KOR agonists have the ability to block the rewarding effects of cocaine (Schenk et al., 1999; Zhang et al., 2004) , but by themselves they have been shown to be aversive (Zhang et al., 2005) . Kappa antagonists have been shown to block stress-induced reinstatement to cocaine seeking in animal self-administration models, but with no effect on drug-induced reinstatement (Beardsley et al., 2005) . In addition to addiction, KOR-directed ligands are attractive potential therapeutics in a range of conditions, including depression, pain, PTSD, pruritis, and others ( Van'T Veer and Carlezon, 2013; Jones et al., 2016) . Additional investigation is needed to determine the effects of different KOR ligands on models of cocaine use.
Recent advances in the molecular pharmacology of G-protein coupled receptors have revealed that effectors of signaling can differentially activate select intracellular mediators, known as ligand bias (Violin and Lefkowitz, 2007) . Ligand bias can be used to describe differences in activation of G-protein subtypes as well as differences in activation between other pathways. In many cases, ligand bias is used to describe differences between G-protein and arrestin signaling pathways. These differences in signaling can in turn yield different in vivo effects for biased vs unbiased compounds, with the potential for favorable clinical properties for biased compounds. This has been shown for biased agonists of the angiotensin receptor (Monasky et al., 2013) and the mu opioid receptor (MOR) (Soergel et al., 2014) . Several recent studies have described kappa opioid receptor (KOR) biased ligands in in vitro studies (including White et al., 2013; Lovell et al., 2015) . Further, 2 studies of G-protein biased vs unbiased KOR agonists indicate that ligand bias can yield disparate effects in vivo at the behavioral level (White et al., 2015; Brust et al., 2016) . Additional investigations on the effects of ligand bias in the KOR system are needed to explore the therapeutic potential for biased KOR ligands.
Several KOR-selective pharmacophores have been recently reported and characterized (Frankowski et al., 2010 (Frankowski et al., , 2012 Nagase et al., 2010; Spetea et al., 2012; Bourgeois et al., 2014; Hirayama et al., 2014; Riley et al., 2014; Scarry et al., 2016) . The current study follows from a report (Spetea et al., 2012) of novel compounds based on a diphenethylamine structural backbone known to interact with the dopamine D2 receptor and reported to also have KOR antagonist activity in in vitro rodent tissue binding assays and bioassays (Fortin et al., 1991) . The novel compounds in this series were studied in KOR radioligand binding and [ 35 S]GTPγS binding stimulation in vitro, with the same assays performed with membranes prepared from cell lines expressing MOR or DOR, as well as dopamine D1, D2, or D3 receptors (Spetea et al., 2012) . The compound that had the highest affinity for KOR was N-methylcyclobutyl-N-phenylethyl-N-3-hydroxyphenylethyl-amine (Figure 1A, MCBPHA, referred to as HS-665, compound 4 in Spetea et al., 2012) . MCBHPA was reported to have 90% intrinsic activity in KOR [ 35 S]GTPγS assays, with low affinity and no agonism at the dopamine D2 receptor. This compound was further characterized in an in vivo acetic acid writhing analgesia assay in mice. It was demonstrated to be equally potent as the well-characterized KOR agonist U50,488 in peripheral analgesia, and the effect was blocked by a KOR antagonist .
Significance Statement
The kappa opioid receptor (KOR) has recently emerged as a potential therapeutic target for addictive diseases as well as other disorders. It is yet to be determined, however, if full receptor activation or just activating certain downstream pathways is best. This study presents side-by-side comparisons of 3 very similar compounds that activate the KOR, but with different signaling properties (referred to as "bias"). The effect of these differences in signaling is investigated in mice. (Spetea et al., 2012) . In an additional recent study, MCBPHA, as well as a structurally related methylcyclopropyl derivative, was further characterized in vitro and in vivo . Of the other remaining compounds reported in the 2012 study, one, Figure 1B) (Spetea et al., 2012) .
The goal of this study was to further characterize the properties of these 2 prior published compounds, BPHA and MCBPHA, with respect to KOR G-protein coupled receptor ligand bias and in vivo kappaergic effects. In addition to BPHA and MCBPHA, we also characterized a structurally related diphenylethylamine derivative - N-methylcyclopentyl-N-phenylethyl-N-3-hydroxyphenylethyl-amine (MCPPHA, Compound 3 in Erli et al. 2017 ; Figure 1C ) that was reported to have full agonist activity in the [
35 S]GTPγS assay (Erli et al., 2017) . We report here the results of in vitro studies characterizing MCPPHA, MCBPHA, and BPHA with respect to differential KOR signaling via β-arrestin-2 vs G-protein-mediated signaling compared with the full agonist U69,593 ( Figure 1E ). We also conducted in vivo studies in C57BL6 mice comparing MCPPHA, MCBPHA, and BPHA with U50,488 ( Figure 1D ). We explored whether KOR-mediated endpoints, including prolactin release and rotarod incoordination, are affected by these compounds in the whole animal. (Spetea et al., 2012) . Mass spectrometric and NMR signals were in agreement. LY2444296 [(S)-3-fluoro-4-(4-((2-(3-fluorophenyl) pyrrolidin-1-yl) methyl)phenoxy)benzamide] was also synthesized by WuXi, with a small portion generously donated by Eli Lilly, which was used to confirm that the WuXi synthesized compound was molecularly identical (as determined by reversed-phase highperformance liquid chromatography retention time). For in vivo studies, BPHA, MCBPHA, MCPPHA, U50,488, and LY2444296 were dissolved in 10% ethanol, 10% Tween-80, and 80% water vehicle. Vehicle had no effect on any of the measures studied and is shown as a control where appropriate.
Materials and Methods

Compounds
Animals
Male C57BL6 mice (9-13 weeks, 20-30g) were used in all studies herein. Mice were housed, 4 to a cage, in sound attenuated chambers with individual light controls, in stress-minimized rooms, with a 12-hour-light/-dark cycle, and food and water were provided ad libitum. All animals were housed for at least 1 week, with daily handling, prior to studies. Animals were housed and euthanized in a manner approved by The Rockefeller University Institutional Animal Care and Use Committee.
In Vitro Assays
Opioid Receptor Binding Membranes from cells stably expressing KOR, MOR, or DOR constructs (PathHunter U2OS hOPRK1, CHO-K1 rOPRM1, and CHO-K1 OPRD1 β-arrestin-2 cell line, DiscoverX) were used. Cells were scraped from tissue culture plates, homogenized with a tissue tearor homogenizer in membrane buffer (10 mM Tris, 100 mM NaCl, and 1 mM EDTA; pH 7.4), and centrifuged at 20 000 g for 30 minutes at 4°C and frozen at -80°C until use. Prior to use, the pellets were resuspended in binding buffer (50 mM Tris-HCl, pH 7.4), homogenized with a dounce homogenizer, and 50 μg incubated with 1. ]DPDPE for kappa, mu, or delta binding, respectively) and the appropriate concentration of compound for 60 minutes at 30°C. Nonspecific binding of radioligand to KOR, MOR, or DOR was determined in the presence of 10 µM norbinaltorphimine, naloxone, or naltrindole, respectively. Membranes with bound tritiated ligand were collected on Whatman GF/B filter paper (Brandel) utilizing a Brandel harvester. Bound tritiated ligand was quantified using a TriCarb-2900TR scintillation counter (Packard) following addition of 4 mL ReadySafe scintillation fluid (Beckman Coulter).
[
S]GTPgammaS Binding
Membranes from U2OS cells (PathHunter U2OS hOPRK1) stably expressing human kappa opioid receptors were used. Cells were scraped from tissue culture plates, homogenized with a tissue tearor homogenizer in membrane buffer (10 mM Tris, 100 mM NaCl, and 1 mM EDTA; pH 7.4), and centrifuged at 20 000 g for 30 minutes at 4°C and frozen at -80°C until use. Prior to use, the pellets were resuspended in assay buffer (50 mM Tris, 100 mM NaCl, 5 mM MgCl 2 , and 1 mM EDTA; pH 7.4) and homogenized with a dounce homogenizer and 50 μg incubated with 0.1 nM 
β-Arrestin-2 Signaling
Experiments were conducted using the PathHunter Detection Kit obtained from DiscoverX. Cells stably expressing KOR, MOR, or DOR constructs (PathHunter U2OS hOPRK1, CHO-K1 rOPRM1, and CHO-K1 OPRD1 β-arrestin-2 cell line, DiscoverX) were plated in 96-or 384-well plates. Cells were stimulated with the compounds for 90 minutes at 37°C followed by incubation for 60 minutes in the presence of galactosidase substrate, yielding chemiluminescent product. Chemiluminescence was measured using a Synergy Neo microplate reader (BioTek). Antagonism assays were done in the same manner in the presence of 300 nM U69,593, 1 uM DAMGO, or 1 µM DPDPE for KOR, MOR, or DOR assays, respectively.
Competitive Model Analysis
Competitive model analysis was performed as described in Stahl et al., 2015 . Dose response curves for [ 35 S]GTPγS and β-arrestin-2 assays were used as well as antagonist β-arrestin-2 dose response curves (as described above) for each test ligand. All curves were fit by nonlinear regression in GraphPad Prism 7.0. U69,593 was used as the reference ligand.
For each analysis, the data was fit to the equations below. The LogK value is the affinity constant of the ligand, either reference or test. LogR is a measure of efficacy and affinity of the ligand, derived from the operational model of partial agonism (Black and Leff, 1983) . LogRA is a measure of the difference between the LogR value of the test ligand and the LogR value of the reference ligand. In these equations, X is the concentration of the test ligand, while A is the concentration of the reference ligand (held constant in the assays where the test ligand is treated as an antagonist). Finally, n is the transducer slope factor that was held to 1 for analysis. For the [ 35 S]GTPγS assays, the U69,593 curve was first fit to the reference ligand equation. These parameters were then used to fit the data from the test ligand. For the β-arrestin-2 assays, the U69,593 curve was first fit to the reference ligand equation. These parameters were then used to fit the data from the test ligand both using the agonist and antagonist equations, when data was available. Initial parameters and constraints were held as described in Stahl et al. 2015 .
Reference ligand: 
In Vivo Assays
Prolactin Assay
Mice were injected i.p. with varying doses of MCBPHA, BPHA, or MCPPHA (or vehicle) 30 minutes prior to sampling. LY2444296 or vehicle pretreatment, if applicable, was given by i.p. injection 60 minutes prior to sampling. Vehicle for all experiments and all compounds except for U50,488 consisted of 10% ethanol, 10% Tween-80, and 80% distilled deionized water. In the case of U50,488 injections, sterile saline was used as the vehicle. Trunk blood was collected by rapid decapitation, followed within 2 hours by preparation of serum. Serum prolactin levels were determined using a commercially available enzyme-linked immunoassay (AbCam) following dilution of serum 5-fold in assay buffer.
Rotarod Assay
Rotarod experiments were conducted with mice using a dedicated rodent rotarod apparatus, with up to 5 animals tested concurrently (IITC Life Science). Rotarod rotation rate begins at 3 rpm, and ramps to 30 rpm over the course of 300 seconds, at which time the assay is terminated and animals removed to their home cage. Animals were acclimated to the rotarod on at least 2 occasions prior to the day of the test. On the day of the test, baseline times for each animal to fall off the rotarod were recorded. Mice were then injected intraperitoneally with vehicle or compound, and rotarod measurements conducted, beginning 0-2 minutes after injection, and then subsequently at select time points thereafter. Animals that failed to remain on the rotarod for at least 150 seconds during baseline testing were removed from the analysis. Additional experiments, with pretreatment of animals with the short-acting kappa antagonist, LY2444296, prior to kappa agonist administration, were also conducted.
Data Analysis
In vitro binding, [
35 S]GTPγS stimulation, and β-arrestin-2 coupling experiments were analyzed using Origin 5.0 software (OriginLab), with sigmoidal fitting to determine parameters of half-maximal concentrations and maximal intrinsic activity. In the case of binding experiments, sigmoidal IC 50 determinations were converted to K i values using the Cheng-Prusoff equation (Yung-Chi and Prusoff, 1973 The reference ligand used for all in vitro assays was U69,593. All in vitro determinations were conducted in a minimum of 3 separate experiments In vivo rotarod and prolactin experiments were analyzed using Statistica 13.0 statistical software (Dell Statistica). For rotarod experiments, 2-way ANOVAs with repeated measures (condition/dose x time, with repeated measures on time) were used to examine effects and/ or interactions of condition/dose and time. For prolactin experiments, 1-way ANOVAs were used to examine effect of condition. In both cases, Newman-Keuls posthoc tests were utilized to examine significant differences. Figure S1 ). Binding to MOR and DOR was also inhibited, but with considerably lower affinity compared to binding at KOR in all cases (Table 1) .
Results
In Vitro Characterization
BPHA, MCBPHA, and MCPPHA exhibited full agonism in the [ 35 S]GTPγS assay (defined as maximal stimulation by U69,593) ( Figure 2A ; Table 2 ). MCPPHA and MCBPHA also exhibited partial agonism in the β-arrestin-2 recruitment assay, while BPHA yielded no stimulation of β-arrestin-2 signaling ( Figure 2B ; Table 2 ). None of the compounds exhibited agonism in the arrestin assays for MOR and DOR (Table S1 ).
These results indicate that BPHA, MCBPHA, and MCPPHA are KOR agonists with bias for G-protein signaling over β-arrestin-2 signaling, albeit with different degrees of bias. To quantify the difference in bias between compounds, we fit the data to the "competitive model" . This model was derived from the traditional operational model of partial agonism (Black and Leff, 1983) to better model agonists with very partial activity. LogRA values from the competitive model describe the difference in efficacy and potency between a test ligand and the reference ligand (U69,593) in a single signaling assay (Table 3 ). The ΔLogRA between 2 pathways is a quantitative measure of the bias of the ligand between those 2 pathways. The bias can also be described using the bias factor, which is defined as the antilog of ΔLogRA (Schmid et al., 2013) . The units of both the ΔLogRA and bias factor are undefined, as is the limit. An unbiased ligand would have similar LogRA values across the 2 pathways. This would yield a ΔLogRA of 0, and therefore a bias factor of 1. and 18.0 (Table 3 ), indicating that they are all G-protein biased agonists with varying degrees of bias Note, this range in bias factors is similar to that recently reported for a structurally related class of MOR agonists (Schmid et al., 2017) . U50,488 has a ΔLogRA value of 0.6 (-0.1 to 1.2), with confidence range inclusive of 0. A bias factor of 4.0 suggests that U50,488 is slightly G-protein biased compared to U69,593 in our assays, but less biased than BPHA, MCBPHA, or MCPPHA.
In Vivo Characterization
Male C57BL6 mice were used to investigate the effects of these compounds on release of prolactin into the systemic circulation, a biomarker of KOR activity. We first verified that a KOR antagonist was able to block the serum prolactin-releasing effects of U50,488. The KOR antagonist used, LY2444296, is a novel, short-acting (<48 hours), selective kappa antagonist that has been shown in rodents to block behavioral effects of kappa agonists (Valenza et al., 2017) . U50,488 was chosen over U69,593 as the reference KOR agonist in vivo due to solubility reasons. Pretreatment of animals with 3 mg/kg LY2444296 blocks the effects of 10 mg/kg U50,488 in stimulating prolactin release ( Figure 3A) . Importantly, KOR antagonism by LY2444296 itself has no effect on prolactin levels, indicating that there is no contribution of endogenous dynorphin/KOR tone on circulating prolactin in the stress-minimized conditions in which the mice in this study were maintained. BPHA and MCBPHA were studied concomitantly for their effects on prolactin ( Figure 3B ). For reasons of compound availability at the time, MCPPHA was studied in a separate experiment ( Figure 3C ). Each of the 3 compounds resulted in increased prolactin, and this rise was antagonized by pretreatment with the KOR antagonist LY2444296. In rotarod studies, BPHA (30 mg/kg) resulted in no motor incoordination, in contrast to the full, unbiased KOR agonist U50,488 ( Figure 4A ). MCPPHA and MCBPHA both resulted in submaximal incoordination on the rotarod assay, with MCPPHA resulting in longer lasting effects, which may result from enhanced arrestin signaling ( Figure 4A ). We show the dose response curves for MCBPHA and MCPPHA ( Figures S4A and S4B) . A 30-minute pretreatment with the short-acting antagonist LY2444296 at a KOR-selective dose (1 mg/kg) blocked the motor incoordination effects of U50,488 ( Figure 4B ), MCBPHA ( Figure 4C ), and MCPPHA ( Figure 4D ).
Discussion
In several publications involving these compounds, Spetea et al. examined the functional activation of G-protein signaling and several in vivo assays (Spetea et al., 2012 Erli et al., 2017 Spetea et al. 2017 ) is also in agreement with recent findings .
We extended the prior studies by investigating signaling through the β-arrestin-2 signaling pathway for all 3 ligands, with calculations of ligand signaling bias, using the model of Stahl et al. 2015 . Qualitatively, ligand bias is understood as enhanced signaling via one intracellular signaling pathway compared with another. G-protein-mediated signaling compared with arrestinmediated signaling for any given ligand can be defined by differences in potency or efficacy compared with a reference ligand . The term "extreme bias" has been used to describe compounds with signaling efficacy in one pathway, but no signaling efficacy in the other. Nalmefene, a well-known MOR antagonist, was described as a KOR partial agonist in humans (Bart et al., 2005) and in vitro using G-protein pathway endpoints. It has recently been shown to be an extremely G-proteinbiased KOR agonist by the group of Bohn as well as in unpublished studies by our group. To quantify bias for this kind of ligand, a model must be used that can accommodate quantifying ligand activity that is very low. Quantification of ligand bias has been described in multiple ways. Bias quantification is based on the Black and Leff model of partial agonism (Ehlert, 2008; Kenakin et al., 2012) ; however, this model becomes less accurate when the partial agonist shows very little activity in the assay. Thus, the competitive model becomes particularly useful in characterizing bias in "extremely" biased ligands.
In this study, BPHA showed full efficacy in the [ 35 S]GTPγS assay and no efficacy in β-arrestin-2 signaling, indicating it to be an "extremely" G-protein biased KOR agonist (Tables 2 and 3; Figure 2B ). All 3 ligands are full agonists in [ 35 S]GTPγS stimulation, with varying efficacy recruiting β-arrestin-2. Our calculations utilizing the model reported by Stahl et al., 2015 demonstrate all compounds to be G-protein biased (Tables 2 and 3 ; Figure 2B ). BPHA has the highest bias factor, as it has no efficacy in β-arrestin-2 signaling. MCBPHA and MCPPHA have lower bias factors, as they both have partial efficacy in β-arrestin-2 signaling.
In prior reports of in vivo activity, Spetea et al. demonstrated efficacy of both MCBPHA (HS665 in Spetea et al. 2012 , compound 1 in Erli et al. 2017) and MCPPHA (compound 3 in Erli et al. 2017) in an analgesia assay in mice. Erli et al. also reported that neither of these compounds caused locomotor defects as measured in the rotarod assay at concentrations up to 10 mg/kg. Here, we demonstrate that both MCBPHA and MCPPHA cause motor incoordination as measured by the rotarod at higher doses. BPHA, however, does not cause such effects up to the dose of 30 mg/ Bias factors greater than 1 indicate G-protein bias. These best-fit parameters were determined by non-linear regression in Graphpad Prism and are presented plus or minus the standard error in parentheses.
kg. These findings indicate that this class of compounds is likely crossing the blood brain barrier, leading to centrally mediated KOR-specific behavioral effects. We have not investigated in detail the pharmacokinetic profiles of these compounds, but substantial behavioral effects are possible in some receptor systems when only a minute fraction of a drug enters the brain, as is the case with morphine (Oldendorf et al., 1972) . There is the possibility that differential effects observed in vivo with these compounds in the rotarod incoordination assay reflect differences in bioavailability, reflecting differences in blood-brain barrier permeability and/or metabolism. The similarity in structure suggests this is not necessarily the case, but they are empirical questions that will require further experiments. We also demonstrate for the first time KOR-mediated prolactin releasing effects for these compounds. For determination of KOR specificity, we utilized the recently developed short-acting KOR antagonist LY2444296. LY2444296 is a close analog of the compound LY2456302, which has been investigated in the clinic (Lowe et al., 2014; Rorick-Kehn et al., 2014; Reed et al., 2017) . Prolactin and rotarod effects of the compounds studied here were blocked by LY2444296 ( Figures 3B and 4C-D) . These experiments used a dose of LY2444296 that inhibits effects of U50,488 in releasing prolactin and causing rotarod incoordination but does not inhibit morphine-induced analgesia in a hot plate assay in C57BL6 mice (data not shown), suggesting it is a KOR-specific dose. A recent report demonstrated that RB-64, a G-protein-biased KOR agonist, had reduced potency in inducing arrestin-mediated signaling but similar maximal efficacy (White et al., 2015) . This G-protein-biased KOR agonist did not have an effect on the rotarod, indicating for the first time that arrestinmediated signaling was important for KOR-mediated rotarod incoordination. This is supported by the in vitro arrestin signaling results and the in vivo behavioral rotarod studies for the compounds under study here. BPHA has no β-arrestin-2 signaling activity and results in no rotarod incoordination. In contrast, MCPPHA and MCBPHA are partial agonists for β-arrestin-2 signaling and result in significant motor incoordination. While additional signaling mechanisms that could contribute to KORinduced incoordination have not been explored, the extent of incoordination correlates with the extent of arrestin activity within these structurally related compounds ( Figure 4A ). The antagonism by BPHA of U69,593 beta-arrestin coupling in vitro ( Figure S3 ) suggests this compound would antagonize U50,488-induced rotarod incoordination and is a possibility for future examination, albeit potentially requiring higher doses than those utilized this study. There have been 2 other recent reports on the in vivo effects of G-protein biased KOR agonists (White et al., 2015; Brust et al., 2016) . Only a single biased compound was profiled for in vivo investigation in each study. Both of these studies reported disparate KOR-mediated behavioral and neurochemical effects of biased vs unbiased compounds. Our investigation, while similar, utilized 3 different structurally related but differentially biased (based on differences in β-arrestin-2 signaling efficacy) compounds to learn more about the relationship between ligand bias (as measured in vitro) and KOR-mediated effects in vivo. The correlation of β-arrestin-2 signaling efficacy in vitro with rotarod incoordination in vivo amongst these 3 structurally similar compounds strongly supports the hypothesis that KOR-mediated incoordination requires arrestin signaling. In vitro data collected in heterologous cell lines often does not accurately reflect in vivo effects, and in fact ligand bias has been shown to vary across cell lines (McLennan et al., 2008) . The rotarod and β-arrestin-2 data for MCBPHA, MCPPHA, and BPHA suggest that in this system, the in vivo data may reflect in vitro findings. Verification of ligand bias in the mouse brain is needed; however, currently there are no assays available for measuring arrestin recruitment in vivo directly . The mechanism by which β-arrestin-2 mediates KOR effects on incoordination as assessed by the rotarod assay is not well understood. There was an investigator-observed sedative effect of the KOR agonists in C57BL6 mice, which is consistent with observations of the effects of KOR agonists in humans (Rimoy et al., 1994) and nonhuman primates (Butelman et al., 2009 ). The rotarod incoordination assay has been utilized as a measure to quantify KOR sedation in rodents (Giardina et al., 1994) . Although rotarod incoordination can also reflect gross disruptions of dopaminergic neurons in the striatum (Fahim et al., 2013) , given the timecourse of the effects of KOR agonists on rotarod behavior it is more likely that the sedation is caused by a different mechanism. This is supported by evidence published for salvinorin A, separately by our laboratory, on the effects of systemic salvinorin A on extracellular dopamine in the caudate putamen (Zhang et al., 2005) , and the effects of systemic salvinorin A on rotarod incoordination (White et al., 2015) . At a dose of 3.2 mg/kg, salvinorin A results in immediate decrease of extracellular dopamine by over 50% in the caudate putamen for at least 3 hours after administration (Zhang et al., 2005) . With a dose of 3 mg/kg salvinorin A, the effects on rotarod incoordination have been reported to begin returning to normal within 30 minutes after injection (White et al., 2015) . Together, these findings suggest that dopamine levels in the striatum may not correlate with the sedative effects of KOR agonists.
Further studies, potentially involving intracerebral microinfusions, will be required to determine the brain regions and precise neurochemical mechanism of KOR-mediated sedation. A review of the sedative effects of the KOR agonist spiradoline, one of the few KOR agonists to have been studied in humans, speculated that a KOR-mediated antihistamine effect underlies the sedative properties (Wadenberg, 2003) . Further studies will be required, but the data presented by the current studies, as well as previous studies with G-protein biased KOR agonists (White et al., 2015; Brust et al., 2016) , strongly suggest that β-arrestin-2-mediated signaling plays a key role.
It has long been established that prolactin can serve as a biomarker of kappa opioid receptor agonism (Butelman et al., 1999; Kreek et al., 1999) , but it is has not previously been investigated with respect to G-protein-biased KOR ligands. The mechanism for KOR regulation of prolactin is via KOR-mediated disinhibition of pituitary lactotrophs, which are tonically inhibited by tuberoinfundibular dopaminergic neurons. KOR agonists block dopamine release from tuberoinfundibular neurons in addition to lowering extracellular dopamine levels in the striatum (Manzanares et al., 1991) . It has been reported that ligands lacking β-arrestin-2 signaling in vitro do not cause KOR-mediated decreases in dopamine release in the nucleus accumbens, suggesting that β-arrestin-2 signaling is necessary for this process (Brust et al., 2016) . Were β-arrestin-2 similarly required for inhibition of dopamine release from tuberoinfundibular neurons, we would anticipate a similar gradation of the effects of the three compounds on prolactin release to that observed for the effects in rotarod incoordination. The fact that each compound with differential arrestin signaling and rotarod incoordination results in similar prolactin release suggests that prolactin release, as a biomarker of KOR activity, does not require arrestin signaling and thus is potentially mediated by KOR G-protein signaling. As mentioned above in the introduction, there are potentially other signaling pathways that could also be involved, and the signaling components present in in vitro heterologously expressing cells may not adequately reflect those mediating KOR signaling in vivo, and in particular in the tuberoinfundibular dopaminergic neurons.
Conclusions
The current findings include the description of an extremely G-protein-biased compound (BPHA) and 2 G-protein biased compounds with differential arrestin efficacy (MCBPHA and MCPPHA) and their effects in vivo. These compounds add to the growing pharmacological toolbox to explore the role of KOR signaling in diverse animal models of addiction, depression, PTSD, pain, pruritis, and other disorders. BPHA, MCBPHA, MCPPHA, and related compounds may prove to be useful tools for delineating the role of differential G-protein bias in the behavioral effects of KOR agonists in animals. This could prove essential for the development of novel KOR ligands as potential pharmacotherapeutics. 
Funding
